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Department of Dermatology, University Hospital of La Coruña, La Coruña, SpainA B S T R A C TBackground: There are numerous clinical trials proving efﬁcacy and
safety proﬁles of etanercept. Newer studies, however, include patients
with signiﬁcant comorbidities, unstable psoriasis, or concomitant
treatments. Objective: The objective of this study was to provide data
on long-term response to etanercept and estimate the cost in daily
practice. Methods: This is an observational retrospective study
including patients with plaque-type psoriasis receiving etanercept
50 mg/wk for more than 6 months at the Dermatology Department of
the University Hospital of La Coruña (Spain). Psoriasis severity was
determined using the Psoriasis Area and Severity Index (PASI) at
baseline and then at 12 weeks, 24 weeks, and annually until treatment
discontinuation. Results: A total of 102 patients aged 24 to 78 years
were included. Response rates of 58.8% and 66.3% for PASI 75 score
(reduction of at least 75% in PASI score compared with baseline) were
achieved after 12 and 24 weeks of treatment, respectively. Among
patients who continued treatment, the PASI 75 score was maintainedee front matter & 2015 Published by Elsevier Inc.
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Coruña, Spain.by 75.3% at 1 year, 82.5% at 2 years, and 88.2% at 3 years. The
percentage of patients receiving other systemic treatments was
38.2%. Adverse effects were reported in 13.7%, all of them mild, except
one case of urinary sepsis. The average cost per patient was €244.68 
€45.27 per week and €34.95  €6.46 per day. Conclusions: We provide
data on long-term response to etanercept and its costs in a real-world
setting. Response rates were higher than in some clinical trials, with
progressive efﬁcacy and not related to body mass index. Etanercept
cost was comparable with that estimated in other studies. Combina-
tion with a conventional systemic agent can enhance efﬁcacy without
additional adverse events.
Keywords: cost, daily clinical practice, efﬁcacy, etanercept, aque-type
psoriasis.
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Pharmacoeconomics and Outcomes Research (ISPOR).Introduction
Etanercept is a tumor necrosis factor alpha antagonist whose
efﬁcacy and safety proﬁles have been proved in numerous clinical
trials. Nevertheless, these studies usually enroll only patients with
stable disease, without signiﬁcant comorbidities, who undergo a
washout period of previous systemic treatments [1–4].
The aim of this study was to provide data on long-term
response to etanercept and estimate the cost for the treatment
of patients with moderate to severe plaque-type psoriasis in daily
clinical practice.Methods
This is an observational retrospective follow-up study including
patients with moderate to severe plaque-type psoriasis receiving
50 mg/wk of etanercept for more than 6 months at the Psoriasis
Unit of the Dermatology Department of the University Hospital of
La Coruña in Spain. We included patients treated with etanerceptbetween January 1, 2005 (the year in which the treatment was
authorized in our hospital), and December 31, 2012. Patients with
intermittent therapy were not excluded. Data were obtained from
chart review and patient interview. All patients signed an
informed consent form to be included in the study.
Baseline demographic and disease status data were collected:
age, sex, body mass index (BMI), psoriasis duration, previous
psoriasis treatments, history of psoriatic arthritis, date of etaner-
cept initiation and dose, duration of treatment, and date and
reason for treatment discontinuation.
Psoriasis severity was determined using the Psoriasis Area
and Severity Index (PASI) at baseline and then at 12 weeks, 24
weeks, and annually until treatment discontinuation. Psoriasis
was considered moderate to severe in patients with a PASI score
of 10 or greater or those receiving systemic treatment for their
psoriasis at study inclusion. Treatment efﬁcacy was assessed in
all patients enrolled in the study at these time points by PASI 75
score (reduction of at least 75% in PASI score compared with
baseline), taking into account the BMI and the dose of etanercept
(50 mg/wk or 50 mg twice weekly).on behalf of International Society for Pharmacoeconomics and
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etanercept, addition of concomitant treatments for psoriasis,
the causes for etanercept discontinuation, the occurrence of
adverse events, their severity, and the relationship with etaner-
cept therapy. Furthermore, we assessed the average cost of
etanercept treatment per patient according to the ofﬁcial selling
price in Spain at the end of the study (€227.806 per 50 mg preﬁlled
syringe), taking into account registered changes in the admin-
istration schedule and doses.Statistical Analysis
All statistical analysis was performed using the Statistical Pack-
age for Social Science, version 18.0, for Windows. Descriptive
statistics such as mean, median, and SDs were computed for
continuous variables, and percentages (%) were used for catego-
rical variables. The chi-square test was used for studying the
relationship between PASI 75 score and BMI. Statistical signiﬁ-
cance was set at P o 0.05.Results
A total of 102 patients aged 24 to 78 years were included. Their
mean age was 52.3  12.4 years; 74.5% were men and 25.5% were
women. The mean duration of psoriasis was 22.0  10.6 years
(range 5–49 years).
Family history of psoriasis was present in 52.6% of the
patients and psoriatic arthropathy in 27.7% of the patients at
the start of etanercept treatment.
Body weight was within normal limits in 20.2% of the patients
(BMI 18.5–24.9 kg/m2). There was overweight in 41.5% (BMI 25–
29.9 kg/m2), obesity in 36.2% (BMI 30–39.9 kg/m2), and morbid
obesity in 2.1% of the patients (BMI of 440 kg/m2).
The mean PASI score at the start of etanercept treatment was
10.6  9.1. The mean duration of etanercept treatment was 124.8
 71.3 weeks in all patients and 91.5  51.8 weeks in patients in
whom treatment discontinuation was necessary because of loss
of efﬁcacy or adverse events (46.0%). The mean duration of
treatment was 166.2  64.9 weeks in patients maintaining treat-
ment at the end of the study.
Five patients (4.9%) received intermittent therapy with eta-
nercept, whereas the remaining patients received continuous
treatment. The usual dose of 50 mg/wk was increased to twice
a week in 19.6% of the patients who failed to respond to the lower
dose, for a mean of 24.1  11.6 weeks, after which the 50 mg/wk
dose was re-established.
The percentage of patients receiving other systemic treat-
ments during the study was 38.2% (9.8% acitretin, 21.6% cyclo-
sporine, 5.9% methotrexate, and 1% phototherapy). The mean
duration of concomitant therapy was 57.7  58.0 weeks with
acitretin, 26.0  14.1 weeks with cyclosporine, 23.0  20.6 weeks
with methotrexate, and 18 weeks in the case of phototherapy.
Concomitant systemic treatment had been started before etaner-
cept in 66.7% of the patients and was continued for a mean of
33.3  39.4 weeks until withdrawal and maintenance of etaner-
cept monotherapy. In the remaining 33.3% of the patients,
concomitant therapy was subsequently added to improve eta-
nercept efﬁcacy and was maintained for a mean of 33.9  15.6
weeks. Concomitant topical treatment was prescribed in all
patients at some point during the study.
Demographic data and psoriasis characteristics are summar-
ized in Table 1. The PASI 75 score was achieved by 58.8% of the
patients at 12 weeks of treatment (60 of 102) and by 66.3% (65 of
102) at 24 weeks. Among patients who continued etanercept
treatment, the PASI 75 score was maintained by 75.3% at 1 year(61 of 81), 82.5% at 2 years (47 of 57), and 88.2% at 3 years (30 of
34). All patients who are still being treated at 4 and 5 years
maintained the PASI 75 score (9 of 9 and 5 of 5 patients,
respectively) (Fig. 1). Treatment efﬁcacy (PASI 75 score at 12 and
24 weeks) was not related to BMI (P ¼ 0.61 and 0.33, respectively).
The reasons for etanercept discontinuation were loss of
efﬁcacy and switch to another treatment in 43.10% and other
reasons in 6.9% (adverse events or loss of patient follow-up) of
the cases. Fifty percent of the patients maintained etanercept
treatment at the time of study completion. Adverse effects were
reported in 13.7% of the patients, all of them mild, except in one
case on etanercept monotherapy, in which treatment withdrawal
was necessary due to urinary sepsis. This was considered as a
serious adverse event that might have been inﬂuenced by
etanercept.
The average cost per patient treated with etanercept was
€244.6  €45.2 per week and €34.9  €6.4 per day. Additional cost
of concomitant systemic and topical therapies was not included
in this calculation.Discussion
Efﬁcacy and safety proﬁles of etanercept have been proved in
numerous controlled clinical trials [1–4]. However, because most
of them exclude patients with signiﬁcant comorbidities, unstable
types of psoriasis, or concomitant treatments, results in daily
practice may be quite different to these trials.
Treatment efﬁcacy (PASI 75 score) at 12 and 24 weeks in our
patients was higher than that observed in some clinical trials,
with response rates of 14% to 49% and 25% to 59% for the PASI 75
score after 12 and 24 weeks of treatment, respectively [2–4]. Some
reports on the use of etanercept in daily practice found that the
efﬁcacy at 12 and 24 weeks was lower than that found in placebo-
controlled trials [5–7]. Because eligibility criteria for biologic
therapy in daily practice require ineffectiveness, intolerance, or
contraindications to classic systemic therapies, the selection of a
more therapy-resistant group of patients compared with clinical
trials could explain these differences.
As in our case, however, other studies in daily practice have
demonstrated similar or even better results than clinical trials [8–
10]. These differences may be due to the use of different dosage
schedules or the addition of concomitant antipsoriatic medica-
tion in daily practice, which might introduce a bias toward more
favorable efﬁcacy outcomes.
In our study, etanercept efﬁcacy was not evaluated as mono-
therapy. Therefore, it is possible that our results about its efﬁcacy
were better than they would have been under controlled clinical
trial conditions. However, we included a high percentage of obese
patients, resistant to classical systemic therapies or with other
comorbidities (hypertension, diabetes mellitus, and dyslipide-
mia), which might negatively inﬂuence etanercept efﬁcacy.
Although the prevalence of metabolic syndrome and cardiovas-
cular risk scores were not calculated in this study, we found a
prevalence of 24.6% of metabolic syndrome and a signiﬁcant
proportion of patients at intermediate and high risk of suffering a
major cardiovascular event in the next 10 years (30.5% and 11.4%,
respectively, based on Framingham risk score) in a population of
395 patients with plaque-type psoriasis [11,12].
Treatment efﬁcacy seems to improve at 24 weeks and at 1
year of treatment, as was observed in other studies [5,9,10,13,14].
Arcese et al. [13] observed that among patients who responded to
etanercept treatment, response (PASI 50 score, deﬁned as Z50%
improvement from baseline in the PASI score, and a PASI score of
o10) was achieved in a higher percentage of patients in more
than 24 weeks of treatment (67.1%) compared with shorter treat-
ment times (25.3%, 5.1%, and 2.5% of the patients achieved
Table 1 – Baseline demographic data, clinical disease characteristics, and treatment costs.
Characteristic n (%) Mean  SD Median Range
Sex
Male 76 (74.5)
Female 26 (25.5)
Age (y) 52.3  12.4 52.0 24–78
Time since diagnosis (y) 22.0  10.6 21.0 5–49
Psoriatic arthropathy 28 (27.7)
Family history of psoriasis 51 (52.6)
Body mass index (kg/m2)
Normal (18.5–24.9) 19 (20.2)
Overweight (25–29.9) 39 (41.5)
Obesity (30–39.9) 34 (36.2)
Morbid obesity (440) 2 (2.1)
PASI score at baseline 10.6  9.1 7.7 0–46.7
Treatment duration (wk) 124.8  71.3 119.0
Intermittent therapy 5 (4.9)
Continuous therapy 97 (95.1)
Concomitant systemic treatment
Acitretin 10 (9.8)
Cyclosporine 22 (21.6)
Methotrexate 6 (5.9)
Phototherapy 1 (1.0)
Treatment cost per day (€) 34.9  6.4 32.5 23.0–60.2
Treatment cost per week (€) 244.6  45.2 227.8 161.4–421.8
PASI, Psoriasis Area and Severity Index.
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tively) [13]. In their study, 80% of the patients achieved the PASI
75 score, which is higher than rates observed in controlled
clinical trials.
Similarly, Puig et al. [14] in a multicentric prospective study at
12-month follow-up observed a PASI 75 response of 64% at week
12, reaching a maximum at week 24 (76.1%) and maintaining to
the end of the study. Van Lümig et al. [5] described the long-term
efﬁcacy of etanercept in real-world practice and although
response rates were lower than in randomized controlled trials,
the percentage of patients achieving the PASI 75 score progres-
sively increased from week 12 (23.6%) to week 24 (38.1%) until the
end of the study at week 24 (60%). As in our case, these results
from European studies suggest that the onset of etanercept
activity may be delayed in some patients and that 12 weeks
may be too short a period to assess efﬁcacy in these cases.
It is well known that obesity, in addition to playing a role in
the pathogenesis of psoriasis, has important implications in the
treatment, such as a greater risk of adverse effects with conven-
tional systemic drugs and reduced efﬁcacy and/or increased cost
with biologic agents; therefore, dosage adjustment should be
considered according to patients’ weight [15]. Although we found
a high percentage of overweight and obese patients, BMI does notPatients on
treatment
months
Patients 
achieving PASI 
ig. 1 – Etanercept efﬁcacy over time. PASI, Psoriasis Area
nd Severity Index. (Color version of ﬁgure available online).seem to be associated with treatment efﬁcacy, unlike other
studies performed in daily practice. The PASI 75 score was
achieved by a higher percentage of patients with a body weight
of 65 kg or less (87.5%) than those with a body weight of 66 to 80
kg (80.5%) or more than 80 kg (74.1%) [13].
There are some studies about the concomitant use of etaner-
cept and other systemic therapies, most of them with metho-
trexate in patients with rheumatic diseases [14–17]. Use of
concomitant antipsoriatic therapy was relatively frequent in our
study, especially during the initial phase of etanercept treatment
because the washout period was not performed before starting
biologic therapy to prevent the progression or relapse of the
disease, which also explains the relatively low PASI scores at
baseline. For one-third of the patients, systemic therapy was
added to achieve a higher response, improving etanercept efﬁ-
cacy without any signiﬁcant adverse event. Our data support that
etanercept in combination with a conventional systemic agent
can enhance efﬁcacy without signiﬁcant additional toxicity and
permit safe transitioning from another systemic therapy.
Although biologic therapy is a safe and effective option in the
treatment of psoriasis, it is much more expensive than conven-
tional systemic therapy. Few studies estimate the cost of these
treatments in daily clinical practice [18].
In another Spanish study, the average cost in the mainte-
nance phase of etanercept treatment (>24 weeks since the start
of treatment) at standard doses was approximately €35/d with
little variation among patients [19]. We obtained similar results.
We estimate, however, the average cost from the start of treat-
ment, including those patients treated with 50 mg twice weekly.Conclusions
We provide data on long-term response to etanercept therapy
and its costs in a real-world setting in La Coruña (Spain).
Response rates were higher than those reported in some clinical
trials, with gradual and progressive efﬁcacy over time and not
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 1 5 8 – 1 1 6 1 1161related to patients’ BMI. Combination with a conventional sys-
temic agent can enhance efﬁcacy without additional adverse
events. Etanercept cost was comparable with that estimated in
other studies.
Source of ﬁnancial support: This study has been supported in
part by a grant from Pﬁzer for Investigator-Initiated Research.
R E F E R E N C E S[1] Papp KA, Tyring S, Lahfa M, et al. Etanercept Psoriasis Study Group. A
global phase III randomized controlled trial of etanercept in psoriasis:
safety, efﬁcacy, and effect of dose reduction. Br J Dermatol 2005;152:
1304–12.
[2] Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy
in patients with psoriasis. N Engl J Med 2003;349:2014–22.
[3] Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of
etanercept as monotherapy for psoriasis. Arch Dermatol
2003;13:1627–32: discussion 1632.
[4] Reich K, Burden AD, Eaton JN, Hawkins NS. Efﬁcacy of biologics in the
treatment of moderate to severe psoriasis: a network meta-analysis of
randomized controlled trials. Br J Dermatol 2012;166:179–88.
[5] Van Lümig PP, Driessen RJ, Boezeman JB, et al. Long-term efﬁcacy of
etanercept for psoriasis in daily practice. Br J Dermatol 2012;166:445–7.
[6] Ahmad K, Rogers S. Two years of experience with etanercept in
recalcitrant psoriasis. Br J Dermatol 2007;156:1010–4.
[7] Warren RB, Brown BC, Lavery D, et al. Biologic therapies for psoriasis:
practical experience in a UK tertiary referral centre. Br J Dermatol
2009;160:162–9.
[8] Jimenez-Puya R, Gomez-Garcia F, Amorrich-Campos V, Moreno-
Gimenez JC. Etanercept: efﬁcacy and safety. J Eur Acad Dermatol
Venereol 2009;23:402–5.[9] Antoniou C, Vergou T, Dessinioti C, et al. Etanercept effectiveness and
safety data on a retrospective study. J Eur Acad Dermatol Venereol
2011;25:1113–5.
[10] Van Lümig PP, Driessen RJ, Kievit W, et al. Results of three analytical
approaches on long-term efﬁcacy of etanercept for psoriasis in daily
practice. J Am Acad Dermatol 2013;68:57–63.
[11] Fernández-Torres R, Pita-Fernández S, Fonseca E. Psoriasis and
cardiovascular risk: assessment by different cardiovascular risk scores.
J Eur Acad Dermatol Venereol 2013;27:1566–70.
[12] Fernández-Torres R, Pita-Fernández S, Fonseca E. Quality of life and
related factors in a cohort of plaque-type psoriasis patients in La
Coruña, Spain. Int J Dermatol 2014;53:507–11.
[13] Arcese A, Aste N, Bettacchi A, et al. Treating psoriasis with etanercept
in Italian clinical practice: prescribing practices and duration of
remission following discontinuation. Clin Drug Investig 2010;30:507–16.
[14] Puig L, Camacho-Martinez FM, Gimeno Carpio E, et al. Efﬁcacy and
safety of clinical use of etanercept for the treatment of moderate to
severe psoriasis in Spain: results of a multicentric prospective study at
12 months follow-up. Dermatology 2012;225:220–30.
[15] Carrascosa JM, Rocamora V, Fernandez-Torres RM, et al. Obesity and
psoriasis: inﬂammatory nature of obesity, relationship between
psoriasis and obesity, and therapeutic implications. Actas
Dermosiﬁliogr 2014;105:31–44.
[16] Famenini S, Wu JJ. Combination therapy with tumor necrosis factor
inhibitors in psoriasis treatment. Cutis 2013;92:140–7.
[17] Foley PA, Quirk C, Sullivan JR, et al. Combining etanercept with
traditional agents in the treatment of psoriasis: a review of the clinical
evidence. J Eur Acad Dermatol Venereol 2010;24:1135–43.
[18] Ruano J, Isla-Tejera B, Jimenez-Puya R, et al. Long-term cost-
effectiveness analysis of etanercept and adalimumab for plaque
psoriasis not associated with arthritis. Dermatol Ther 2013;3:131–42.
[19] Puig L, Morales-Munera C. Implementing therapeutic goals in
maintenance treatment of psoriasis with biologics: adalimumab can be
more cost-effective than inﬂiximab or ustekinumab in real life. Eur J
Dermatol 2013;23:407–8.
